Patient with vaginal cancer with DDR mutation benefits from clinical trial
In March 2019, Shelly Busby began experiencing unusual vaginal bleeding. Frightened and concerned, she went to her OB/GYN for an examination and biopsy.
“There was something there that didn’t belong,” says Shelly, 67, a retired schoolteacher. “There was a tumor, and before I knew it, I was having surgery to have it removed.”
She was diagnosed with stage III vaginal cancer, for which there is currently no approved therapy...
What to expect when you meet with an oncofertility specialist
For people who hope to have children of their own, a cancer diagnosis can derail those plans. However, thanks to oncofertility experts, who...
COVID-19 vaccines and mammograms: 7 things to know
Could getting a COVID-19 vaccine affect the results of your mammogram or other diagnostic imaging exams?
Physicians at MD Anderson...
Targeting the KRAS mutation for more effective cancer treatment
Since the discovery of KRAS gene mutations in 1983, researchers have worked to develop new therapies that target this protein when treating cancer. Unfortunately, KRAS mutations have long been considered impossible to treat with drugs, but MD Anderson researchers have made recent breakthroughs in developing targeted therapies with promising results.
Shubham Pant, M.D., associate professor of Investigational Cancer Therapeutics...
Nanomedicine: Small particles with huge possibilities for cancer care
Nanomedicine is a quickly emerging area of study that uses nanoparticles for drug delivery, diagnoses and in vivo imaging. While nanomedicine...